Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.56 |
| ▸ | NPC1 | O15118 | 10/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.53 |
| ▸ | RELA | Q04206 | 3/20 | 0.53 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.50 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.50 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 2/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19376820 | 0.92 | RAB9A (0.56) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL19376911 | 0.83 | RAB9A (0.53) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL19376847 | 0.83 | RAB9A (0.54) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL19376908 | 0.82 | RAB9A (0.54) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL19376862 | 0.82 | RAB9A (0.53) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL19376907 | 0.82 | NPC1 (0.53) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL19376876 | 0.82 | RAF1 (0.61) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL19376853 | 0.79 | KDR (0.55) | RAB9ANPC1CSF1RRAF1LYN | |
| SCHEMBL19376838 | 0.78 | RAB9A (0.60) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL19376823 | 0.78 | RAB9A (0.60) | RAB9ANPC1CSF1RRAF1LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789086-B1 | N-(5-arylamido-2-methylphenyl)-5-methylisooxazole-4-carboxamide deravative, pharmaceutical acceptable salt thereof, method for preparation therof and FMS kinase inhibitor comprising the same as anactive ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-10-17 | — | — | US | claimed |
| US-20170273947-A1 | N-(5-ARYLAMIDO-2-METHYLPHENYL)-5-METHYLISOOXAZOLE-4-CARBOXAMIDE DERAVATIVE, PHARMACEUTICAL ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION THEROF AND FMS KINASE INHIBITOR COMPRISING THE SAME AS ANACTIVE INGREDIENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-09-28 | — | — | US | claimed |
| US-9789086-B1 | N-(5-arylamido-2-methylphenyl)-5-methylisooxazole-4-carboxamide deravative, pharmaceutical acceptable salt thereof, method for preparation therof and FMS kinase inhibitor comprising the same as anactive ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-10-17 | — | — | US | disclosed |
| US-9789086-B1 | N-(5-arylamido-2-methylphenyl)-5-methylisooxazole-4-carboxamide deravative, pharmaceutical acceptable salt thereof, method for preparation therof and FMS kinase inhibitor comprising the same as anactive ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-10-17 | — | — | US | disclosed |
| US-20170273947-A1 | N-(5-ARYLAMIDO-2-METHYLPHENYL)-5-METHYLISOOXAZOLE-4-CARBOXAMIDE DERAVATIVE, PHARMACEUTICAL ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION THEROF AND FMS KINASE INHIBITOR COMPRISING THE SAME AS ANACTIVE INGREDIENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-09-28 | — | — | US | disclosed |
| US-20170273947-A1 | N-(5-ARYLAMIDO-2-METHYLPHENYL)-5-METHYLISOOXAZOLE-4-CARBOXAMIDE DERAVATIVE, PHARMACEUTICAL ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION THEROF AND FMS KINASE INHIBITOR COMPRISING THE SAME AS ANACTIVE INGREDIENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273947-A1 | N-(5-ARYLAMIDO-2-METHYLPHENYL)-5-METHYLISOOXAZOLE-4-CARBOXAMIDE DERAVATIVE, PHARMACEUTICAL ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION THEROF AND FMS KINASE INHIBITOR COMPRISING THE SAME AS ANACTIVE INGREDIENT | ABL1, FLT3, MERTK | RAB9A 3296/4885NPC1 3572/4885MAPT 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.